Document Type

Article

Publication Date

2-13-2018

JAX Source

Oncotarget 2018; 9(8):10497-10509.

PMID

29535822

DOI

https://doi.org/10.18632/oncotarget.24041

Grant

CA127001

Abstract

Background: Despite the availability of hundreds of cancer drugs, there is insufficient data on the efficacy of these drugs on the extremely heterogeneous tumor cell populations of glioblastoma (GBM).

Results: The PKIS of 357 compounds was initially evaluated in 15 different GSC lines which then led to a more focused screening of the 21 most highly active compounds in 11 unique GSC lines using HTS screening for cell viability. We further validated the HTS result with the second-generation PLK1 inhibitor volasertib as a single agent and in combination with ionizing radiation (IR).

Conclusions: Our results reinforce the potential therapeutic efficacy of volasertib in combination with radiation for the treatment of GBM.

Methods: We used high-throughput screening (HTS) to identify drugs, out of 357 compounds in the published Protein Kinase Inhibitor Set, with the greatest efficacy against a panel of glioma stem cells (GSCs), which are representative of the classic cancer genome atlas (TCGA) molecular subtypes.

Oncotarget 2018; 9(8):10497-10509.

Comments

This is an open access article under a Creative Commons Attribution 3.0 License.

Share

COinS